Browse by author
Lookup NU author(s): Dr Aaron Wetten, Professor David Jones, Dr Jess Dyson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: Generic fibrates are used off-label as add-in therapy for the management of primary biliary cholangitis (PBC) but with unproven long-term liver-related survival benefits. The recently developed fibrate, seladelpar, has shown promising results in clinical trials, but these outcomes have been previously marred by safety concerns. Areas covered: We summarize existing treatment options in PBC and evaluate current trial data for seladelpar in relation to liver biochemistry, symptomology, and safety. Expert opinion: Seladelpar leads to marked improvement in liver biochemistry and may improve symptoms. Safety concerns around liver toxicity appear to have been addressed. With likely increasing evidence compared to existing off-label fibrates, seladelpar has the potential as an attractive future second-line agent in PBC.
Author(s): Wetten A, Jones DEJ, Dyson JK
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Investigational Drugs
Year: 2022
Volume: 31
Issue: 10
Pages: 1101-1107
Online publication date: 04/10/2022
Acceptance date: 27/09/2022
ISSN (print): 1354-3784
ISSN (electronic): 1744-7658
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/13543784.2022.2130750
DOI: 10.1080/13543784.2022.2130750
PubMed id: 36194037